Canine hemophilia B resulting from a point mutation with unusual consequences. by Evans, J. P. et al.
Proc. Nadl. Acad. Sci. USA
Vol. 86, pp. 10095-10099, December 1989
Medical Sciences
Canine hemophilia B resulting from a point mutation with
unusual consequences
(factor IX/enzymatic ampIflication)
JAMES P. EVANS*t, KENNETH M. BRINKHOUSt§, GARY D. BRAYER¶, HOWARD M. REISNER§,
AND KATHERINE A. HIGH*t§I1
Departments of *Medicine and SPathology, and §Center for Thrombosis and Hemostasis at The University of North Carolina, Chapel Hill, NC 27599;
and SDepartment of Biochemistry, University of British Columbia, Vancouver, BC, V6T 1W5 Canada
Contributed by Kenneth M. Brinkhous, September 11, 1989
ABSTRACT We have used the polymerase chain reaction
to amplify the entire coding region of canine factor IX from a
hemophilia B animal. When the sequence was compared to that
which codes for normal canine factor IX, a single missense
mutation was identified. This mutation (G -- A at nucleotide
1477) results in the substitution ofglutamic acid for glycine-379
in the catalytic domain of the molecule. The mutation creates
a new restriction site that allowed confirmation of the abnormal
sequence in both hemophilic and carrier animals. Amino acid
379 in canine factor IX corresponds to position 381 in human
factor IX, a location at which no human mutations have been
described. Moreover, it occurs at one of the few amino acids
that have been rigorously conserved among the trypsin-like
serine proteases throughout evolution. The mutation respon-
sible for canine hemophilia B results in a complete lack of
circulating factor IX in the affected animals. As it is unusual for
a missense mutation to result in a complete absence of protein
product, structural modeling of the mutant and normal pro-
teins was pursued. These studies suggest that the observed
mutation would have major adverse effects on the tertiary
structure of the aberrant factor IX molecule. The elucidation
of this mutation sheds light on structure-function relationships
in factor IX and should facilitate future experiments directed
toward gene therapy of this disease.
Factor IX is a 56-kDa plasma glycoprotein that is required for
blood coagulation (1). Factor IX circulates as a zymogen; to
become active in coagulation, factor IX must undergo limited
proteolytic cleavage by factor XIa or factor VIIa-tissue
factor. This proteolytic step cleaves two peptide bonds to
generate a short amino acid segment termed the activation
peptide and unblocks the active site of the enzyme. This
activated form, designated factor IXa, in the presence of its
cofactor factor Villa and calcium and phospholipids, cleaves
factor X to generate factor Xa, the next step in the coagu-
lation cascade. Factor IX belongs to the seine protease
superfamily, a class of enzymes that includes trypsins as well
as coagulation and complement proteins, among others (2).
These enzymes arose early in evolution and are present in
organisms from bacteria to man. Through evolution, they
have acquired a variety of specialized functions. The serine
proteases of the coagulation cascade possess, in addition to
a trypsin-like active site, domains that are thought to confer
cofactor and receptor specificity.
Analysis of the genomic organization of the human factor
IX gene has provided insight into the structure of the protein.
The gene contains eight exons that can be correlated in a
rough way with the functional domains of the protein (3).
Exon I codes for the signal sequence, exon II codes for the
y-carboxyglutamic acid-rich region, exon III codes for the
short aromatic acid stack, exons IV and V code for the
epidermal growth factor-like domains, exon VI codes for the
activation peptide, and exons VII and VIII code for the
catalytic domain and the long 3' untranslated region, respec-
tively. Although genomic structure has been reported only
for human factor IX, acDNA sequence is available for canine
factor IX (4), and the amino acid sequence is available for
bovine factor IX (5). Comparison of sequences among these
species reveals >90% conservation of residues in the y-
carboxyglutamic acid-rich region and in the heavy chain and
a much lower degree of conservation in the activation pep-
tide.
An absence of functional factor IX results in the sex-linked
bleeding disorder hemophilia B. Current treatment of hemo-
philia B requires the infusion of factor IX-rich plasma con-
centrates during bleeding episodes. Such treatments must be
repeated with each episode of bleeding and carry a risk of
contamination by infectious agents. The possibility of treat-
ing hemophilia B by gene therapy has been proposed; one
approach would involve the introduction of a gene encoding
factor IX into the somatic cells of an affected individual.
Hemophilia B is an attractive target for gene transfer therapy
since neither precise regulation of factor IX levels nor
tissue-specific expression is required. A further advantage is
the existence of an animal model of hemophilia B (6, 7), a
potentially valuable resource in trials of gene therapy (8, 9).
To maximize the utility of canine hemophilia B in such
studies, it is desirable to know the causative mutation at the
molecular level. In this report we describe the isolation and
characterization of the cDNA encoding mutant (hemophilic)
canine factor IX. The molecular defect responsible for this
strain of canine hemophilia B is a missense mutation in a
highly conserved residue of the catalytic domain; it results in
a complete lack of detectable protein in the circulation of the
affected animals.
MATERIALS AND METHODS
Canines. Normal, carrier, and factor IX-deficient canines
are maintained at the Francis Owen Blood Research Labo-
ratory, The University of North Carolina at Chapel Hill.
Determination of Factor IX Antigenic Levels in Hemophilic
Canines. Quantitation of circulating factor IX levels was by
ELISA (10). All samples were assayed in duplicate. In
addition, a radioimmunoassay utilizing an affinity-purified
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rabbit anti-canine factor IX antibody was performed by
Arthur Thompson (Puget Sound Blood Center, Seattle).
Isolation of Hepatic DNA and RNA: Southern and Northern
Blot Analysis. High molecular weight DNA was extracted
from hemophilic canine liver by a modification of the method
of Blin and Stafford (11). Total RNA was isolated from frozen
(-700C) dog liver using the guanidinium thiocyanate method
of Chirgwin et al. (12). For Southern (13) and Northern (14)
blot analysis, a 32P-labeled human factor TX cDNA was used
as a probe (15).
Reverse Transcription and DNA Amplification. Synthesis of
single-stranded complementary DNA from a template of total
hepatic RNA was carried out by the method of Gubler and
Hoffman (16) with several modifications (4). (dT)12_18 was
used as a primer for reverse transcription.
Amplification offactor IX reverse transcripts was achieved
by subjecting the single-stranded cDNA to the polymerase
chain reaction (PCR) (17). Priming oligonucleotides were
based on the sequence of normal canine factor IX (4). A
typical experiment involved reverse transcription of 50 ,ug of
total hepatic RNA. The reaction mixture was extracted with
phenol and chloroform and precipitated overnight in ethanol
at -20'C. Twelve percent of the total was centrifuged,
washed, and dissolved in 10 Al of lOx PCR buffer (670 mM
Tris-HCl, pH 8.8/67 mM EDTA/100 mM 2-mercapto-
ethanol/166 mM (NH4)2SO4/67 mM MgCI2). The final vol-
ume of the reaction was 100 1.d and contained 10% (vol/vol)
dimethyl sulfoxide, 1.5 mM deoxynucleoside triphosphates,
oligonucleotide primers (each at a concentration of 0.5 ,uM),
and 2.5 units of thermostable polymerase (Cetus). Amplifi-
cation was carried out manually with an initial denaturing
step at 94°C for 7 min. Annealing was at 55°C for 3 min,
extension at 70°C for 4 min, and denaturation at 94°C for 3
min. The reactions were subjected to 35 cycles of amplifica-
tion after which agarose electrophoresis and electroelution
were used to isolate the appropriate fragments. When ge-
nomic DNA was used as starting material, a 133-base-pair-
(bp) fragment containing the mutation was amplified. Priming
oligonucleotides were constructed based on the normal ca-
nine sequence (4) (GenBank accession no. M21757). Dde I
(New England BioLabs) was used according to manufactur-
er's recommendations.
Subcloning and DNA Sequencing. The termini of the am-
plified DNA were phosphorylated with T4 nucleotide kinase
(New England BioLabs) and the fragments were subcloned
into dephosphorylated M13 vectors. Sequencing was by the
method of Sanger et al. (18), and in certain regions oligonu-
cleotides were constructed for use as primers in the sequenc-
ing reactions. The entire coding region of factor IX as well as
149 bp of 3' untranslated material were sequenced in both
orientations. When discrepancies arose between the normal
canine factor IX sequence (4) and that obtained from the
hemophilic animal, the area in question was subjected to two
additional independent amplifications from newly synthe-
sized cDNA to eliminate the possibility of a polymerase error
masquerading as a mutation.
Amino Acid Sequence Alignment and Structural Modeling.
Alignment of the primary structure of the protease domain of
canine factor IX with those of human factor IX, trypsin,
chymotrypsin, elastase, kallikrein, and Streptomyces griseus
protease A was based on sequence identity and structural
topological equivalence (19-21). Modeling of human factor
IX has been described (21) and was based primarily upon the
known high-resolution structure of bovine pancreatic trypsin
(22).
RESULTS
Quantitation of Factor IX Levels in Canines. The ELISA
which was employed relies on a monoclonal capture antibody
mapped to the first epidermal growth factor-like domain of
human factor IX and a polyclonal antibody raised to human
factor IX. Due to the extensive conservation that exists
between human and canine factor IX (4), this assay is able to
detect the canine protein specifically at plasma dilutions of
1:320. When plasma from factor IX-deficient canines was
analyzed in this assay, no factor IX was detected (data not
shown). These results were confirmed and extended by a
radioimmunoassay that utilized a polyclonal rabbit anti-
canine factor IX antiserum. This assay is able to detect canine
factor IX at plasma concentrations of <0.3%. When coded
samples were assayed by this method, again no factor TX was
detectable.
Restriction Mapping of the Factor IX Gene and Analysis of
the Transcript. Southern blots of normal and hemophilic
canine genomic DNA probed with a factor IX cDNA were
identical (data not shown), indicating that canine hemophilia
B does not result from a grossly detectable abnormality of the
factor IX gene. Total hepatic RNA from normal and hemo-
philic canines was subjected to Northern blot analysis, as
shown in Fig. 1. Hemophilic animals produce a factor IX
transcript; it is similar in size (approximately 3 kilobases) to
the normal and is present at approximately the same steady-
state levels.
Nucleotide Sequence Analysis of Hemophilic Canine Factor
IX. The data from Southern and Northern blot analyses
indicated that a point mutation most likely accounted for the
defect in canine hemophilia B. Therefore, total hepatic RNA
from a factor IX-deficient animal was subjected to reverse
transcription, and the coding region of canine factor IX was
amplified by the PCR technique. Amplification utilized pairs
of oligonucleotide primers flanking the entire coding region of
canine factor IX, including 5' and 3' untranslated sequence.
The ends of the amplified fragments overlapped so that any
mutation present in a region where a primer annealed would
be detected. Sequencing revealed a missense mutation at
nucleotide 1477 (G -- A) in the region encoding the catalytic
domain of the hemophilic factor IX gene (Fig. 2). This
mutation changes a glycine to a glutamic acid in the heavy
chain of the molecule (amino acid 379 in the canine). It
corresponds to amino acid 381 in human factor IX and
position 211 in the chymotrypsinogen numbering system of
the trypsin-like serine proteases. This is the only difference
in the sequence of normal and hemophilic canine factor IX,
throughout the coding region and throughout 149 bases of
untranslated sequence. This region was subjected to three
independent amplifications of newly synthesized cDNA and
identical results were obtained on sequencing in each case.
The mutation that we describe creates a new restriction





FIG. 1. Northern blot analysis of total RNA from hemophilic
(lane A) and normal (lane B) canine hepatocytes. Each lane was
loaded with 10 pkg of total liver RNA. Blots were probed with a
1500-bp nick-translated fragment of normal canine factor IX (4).
Positions of 28S and 18S rRNA are indicated.
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FIG. 2. Nucleotide sequences of hemophilic and normal canine factor IX along with the respective translation products between amino acid
positions 377 and 381. The change from a guanine to an adenine in the hemophilic animal results in the substitution of glutamic acid for glycine
at position 379.
determine whether other animals within the colony had the
same mutation. A 133-bp fragment surrounding the mutation
was amplified by PCR from genomic DNA and digested with
Dde I. The results, shown in Fig. 3, demonstrate that the four
normal animals tested do not contain the mutation and that
the carrier and hemophilic animals do (demonstrated by the
presence of the 79-bp and 54-bp fragments).
Protein Alignment. The catalytic domain of the trypsin-like
serine proteases has been highly conserved throughout evo-
lution. Amino acid alignment of the members of this family of
proteases demonstrates that certain amino acids have re-
mained invariant from bacteria to humans. Fig. 4 shows the
amino acid alignment of the heavy chain of canine factor IX
with the corresponding region of several other serine prote-
ases (human factor IX, trypsin, elastase, chymotrypsin,
kallikrein, and Streptomyces griseus protease A). As can be
seen, the mutation in canine factor IX affects one of these
highly conserved amino acids, substituting a negatively
charged residue (glutamic acid) for an amino acid that is
uncharged and possesses no side chain (glycine).
Structural Modeling. The substitution ofa glutamic acid for
a glycine within the catalytic domain of canine factor IX
would be likely to have profound structural consequences.
To investigate this possibility further, a structural model of
the mutant protein was constructed. Fig. 5A shows a struc-
tural model of the heavy chain of human factor IX. This
should be representative of the structure of the canine
molecule, since, for the amino acids illustrated, there is
complete conservation in identity between human and canine
factor IX. Fig. 5B depicts this region after substitution of a
glutamic acid for glycine at position 381, the mutation found
in the hemophilic canine. This model suggests that substitu-
tion of a glutamic acid at position 211 leads to prohibitive
spatial conflicts with several residues (Leu-162, Phe-181,
His-199, and Tyr-228) and alters the hydrophobic character of
this closely packed and internal region of factor IX.
DISCUSSION
The characterization of mutations that give rise to hemophilia
B in humans has provided insight into critical functional
regions of the factor IX molecule. Since the heavy chains of
human and canine factor IX show remarkable identity (4), our
description of the mutation responsible for canine hemophilia
B provides similar insight into structure-function relation-
ships of the human molecule. There has been no previous
report of a human mutation at the site corresponding to the
one we report here in canine hemophilia (position 379 in
canine and position 381 in human factor IX). This mutation
occurs at a residue that has remained invariant in serine
proteases from bacteria to humans. The profound effect of
the mutation on factor IX levels suggests that the glycine at
position 379 (position 211 in the chymotrypsinogen number-
ing system) plays a critical role in the integrity of the
trypsin-like serine proteases in general.
Hemophilia B has been classified traditionally as either
cross-reacting-material-positive in which antigenically de-
tectable protein is present or cross-reactive-material-
negative in which protein is not detected. The hemophilic
canines were found to have undetectable levels of factor IX
by two independent assays. This represents an unusual
situation among factor IX mutations, since in those charac-
terized to date, missense mutations have always resulted in
detectable levels of factor IX (23). Indeed, it is unusual in
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FIG. 3. Dde I analysis of amplified fragment coding for the region
of the heavy chain containing the mutation. (Upper) Dde I recognizes
the nucleotide sequence CTNAG, where N is any nucleotide. The G
-- A transition in the hemophilic allele results in the creation ofa new
restriction site for Dde 1. (Lower) Lanes: 1-4, PCR-amplified DNAs
from four unrelated normal canines were not cleaved by Dde I and
thus do not contain the mutation; 5-8, PCR-amplified DNAs from
hemophilic animals have only the 79- and 54-bp fragments; 9,
PCR-amplified DNA from a carrier animal has the 133-bp fragment
from the normal allele and the 79- and 54-bp fragments from the
mutant allele; M, marker lane containing 4X174 digested with Hae
IMl.
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FIG. 4. Amino acid sequence alignment of the protease domain of canine factor IX (CFIX) with human factor IX (HFIX), bovine trypsin
(TRYP), porcine elastase (ELAS), bovine chymotrypsin (CHYM), porcine kallikrein (KALL), and Streptomyces griseus protease A (SGPA).
Conserved amino acids are boxed. The position of the mutation in canine hemophilia is denoted by an asterisk. The numbering system is that
of chymotrypsinogen A, and deletions are indicated by dashes.
detectable translated protein. For example, >400 missense
mutations have been described in the globins (representing
25% of all possible mutations) (24) and only 2 of these (25, 26)
result in stable mRNA but a lack of detectable protein in the
circulation. Similarly, severe a1-antitrypsin deficiency has
been found to result from deletions or premature termination
codons 'but has thus far not' been attributed to a missense
mutation. Among >80 missense mutations analyzed in a1-
antitrypsin deficiency, all result in the production of appre-
ciable levels of protein (27).
Northern blot analysis (Fig. 1) indicated that factor IX
mRNA is present in similar steady-state levels in the normal
and' hemophilic dogs, suggesting that failure of expression
occurs at a posttranscriptionaIl level. Several explanations
could account for the absence ofdetectable protein, including
decreased translation, impaired secretion, or production of
an unstable polypeptide. Structural modeling of factor IX
suggests' that folding of the mutant protein is likely to be
severely disrupted and thus offers a possible explanation for
the absence of factor IX. The tertiary structure of factor IX
has not been determined using x-ray diffraction techniques;
however, firm structural data exist for a number of trypsin-
like serine proteases, and there is good reason to believe that
the degree of sequence identity that exists between the
clotting proteins and other members of this enzyme family
translates into a high degree of structural homology (20, 21,
28). Examination of the factor IX model predicts that the
presence of a glutamic acid side chain at position 211 would
result in significant steric hindrance that in turn would cause
improper folding ofthe molecule and structural instability. As
Fig. 5 shows, replacement of glycine with a glutamic acid
residue results in prohibitively close contacts with Leu-162,
Phe-181, His-199, and Tyr-228, all ofwhich are tightly packed
together in this central and internal region of the enzyme.
Furthermore, the charged character of the glutamic acid side
chain is incompatible with the hydrophobic nature of these
surrounding residues.
The fact that other hemophilic animals demonstrate the
same mutation does not eliminate the possibility that the
mutation we describe is a tightly linked polymorphism;
however, it does demonstrate unequivocally that the muta-
tion segregates with the hemophilic phenotype. This, coupled
with the structural modeling data and the absence of any
other mutations, strongly suggests that the glycine -- glu-
tamic acid change is indeed the causative mutation.
The canine model of hemophilia B represents a valuable
resource in trials of gene therapy, and the characterization of
the defect will facilitate use of the animal model. The lack of
antigenically detectable factor IX is an advantage for gene
therapy trials, since even low levels of expression of a foreign
factor IX gene should be readily distinguished from baseline.
We thank Dr. Arthur Thompson whose canine factor IX radioim-
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FIG. 5. (A) Stereodrawing of
human factor IX catalytic domain.
(B) Stereodrawing ofhuman factor
IX with glutamic acid substituted
for glycine at position 211.
graphics support, and Sherry Stanfield-Oakley and the staff of the
Francis Owen Blood Research Laboratory for valuable technical
assistance. This work was supported by Grants HL01648, HL06350,
and HL26309 from the National Institutes of Health. J.P.E. was
supported by a Judith Graham Pool research fellowship in hemophilia
from the National Hemophilia Foundation and K.A.H. was sup-
ported by Clinical Investigator Award K08-HL01922 from the Na-
tional Heart, Lung and Blood Institute. G.D.B. was supported by a
Medical Research Council of Canada operating grant.
1. Furie, B. & Furie, B. C. (1988) Cell 53, 505-518.
2. Neurath, H. (1984) Science 224, 350-357.
3. Yoshitake, S., Schach, B. G., Foster, D. C., Davie, E. W. &
Kurachi, K. (1985) Biochemistry 24, 3736-3750.
4. Evans, J. P., Watzke, H. H., Ware, J. L., Stafford, D. W. &
High, K. A. (1989) Blood 74, 207-212.
5. Fujikawa, K., Legaz, M. E., Kato, H. & Davie, E. W. (1974)
Biochemistry 22, 4508-4516.
6. Brinkhous, K. M., Davis, P. D., Graham, J. B. & Dodds, W. J.
(1973) Blood 41, 577-585.
7. Brinkhous, K. M., Hedner, U., Garris, J. B., Diness, V. &
Read, M. S. (1989) Proc. Natl. Acad. Sci. USA 86, 1382-1386.
8. St. Louis, D. & Verma, I. M. (1988) Proc. Natl. Acad. Sci.
USA 85, 3150-3154.
9. Palmer, T. D., Thompson, A. R. & Miller, A. D. (1989) Blood
73, 438-445.
10. Denton, P. H., Fowlkes, D. M., Lord, S. T. & Reisner, H. M.
(1988) Blood 72, 1407-1411.
11. Blin, N. & Stafford, D. W. (1976) Nucleic Acids Res. 3,
2303-2308.
12. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J. & Rutter,
W. J. (1979) Biochemistry 18, 5294-5299.
13. Southern, E. (1975) J. Mol. Biol. 98, 503-517.
14. Thomas, P. S. (1980) Proc. NatI. Acad. Sci. USA 77, 5201-
5205.
15. McGraw, R. A., Davis, L. M., Noyes, C. M., Lundblad,
R. L., Roberts, H. R., Graham, J. B. & Stafford, D. W. (1980)
Proc. Nail. Acad. Sci. USA 82, 2847-2851.
16. Gubler, V. & Hoffman, B. J. (1983) Gene 25, 263-269.
17. Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi,
R., Horn, G. T., Mullis, K. B. & Erlich, H. A. (1988) Science
239, 487-491.
18. Sanger, F., Nicklen, S. & Coulson, A. R. (1977) Proc. NatI.
Acad. Sci. USA 74, 5463-5467.
19. Cool, D. E., Edgell, C.-J. S., Louie, G. V., Zoller, M. J.,
Brayer, G. D. & MacGillivray, R. T. A. (1985) J. Biol. Chem.
260, 13666-13676.
20. James, M., Delbaere, L. & Brayer, G. D. (1978) Can. J.
Biochem. 56, 396-402.
21. Geddes, V. A., Le Bonniec, B. F., Louie, G. V., Brayer,
G. D., Thompson, A. R. & MacGillivray, R. T. A. (1989) J.
Biol. Chem. 264, 4689-4697.
22. Marquart, M., Walter, J., Deisenhofer, J., Bode, W. & Huber,
R. (1983) Acta Crystallogr. Sect. B 39, 480-487.
23. Lozier, J. N. & High, K. A., Hematologic Pathology, in press.
24. Bunn, H. F. & Forget, B. G. (1986) Hemoglobin: Molecular,
Genetic, and Clinical Aspects (Saunders, New York), pp.
223-321.
25. Liebhaber, S. A. & Kan, Y. W. (1983) J. Clin. Invest. 71,
461-466.
26. Adams, J. G., Steinberg, M. H., Boxer, L. A., Baehner, R. L.,
Forget, B. G. & Tsistrakis, G. A. (1979) J. Biol. Chem. 254,
3479-3482.
27. Brantly, M., Nukiwa, T. & Crystal, R. G. (1988) Am. J. Med.
84, Suppl. 6A, 13-31.
28. Madison, E. L., Goldsmith, E. J., Gerard, R. D., Gething,
M.-J. H. & Sambrook, J. F. (1989) Nature (London) 339,
721-724.
B
Medical Sciences: Evans et al.
